Dihydrolevobunolol is a potent ocular beta-adrenoceptor antagonist.

Abstract

The ocular beta-adrenoceptor antagonist activity of dihydrolevobunolol (DHLB), the major ocular and systemic metabolite of levobunolol was investigated by determining its ability to block isoproterenol-induced ocular hypotension in normotensive rabbits. Topically-applied 0.001% and 0.01% DHLB virtually abolished the response to isoproterenol, indicating a beta-blocking potency similar to that of timolol. Thus, the ocular metabolism of levobunolol leads to the formation of a highly potent beta-adrenoceptor antagonist that may contribute to its clinical efficacy.

• Authors: D F Woodward, G D Novack, L S Williams, A L Nieves, D E Potter
• Journal: Journal of ocular pharmacology (J Ocul Pharmacol) Vol. 3 Issue 1 Pg. 11-5 ( 1987) ISSN: 8756-3320 [Print] United States
• PMID: 2903201 (Publication Type: Journal Article)

Chemical References

• Adrenergic beta-Antagonists
• dihydrobunolol
• Levobunolol
• Isoproterenol

Topics

• Adrenergic beta-Antagonists (pharmacology)
• Animals
• Chemical Phenomena
• Chemistry
• Eye (drug effects)
• Female
• Intraocular Pressure (drug effects)
• Isoproterenol (antagonists & inhibitors, pharmacology)
• Levobunolol (analogs & derivatives, pharmacology)
• Male
• Rabbits